Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Mineralys Therapeutics, Inc. (MLYS) had Return on Equity of -6.41% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-36.93M |
|
-- |
|
-- |
|
$41.13M |
|
$-41.13M |
|
$4.20M |
|
$-36.93M |
|
$-36.93M |
|
$-36.93M |
|
$-36.93M |
|
$-36.93M |
|
$-36.93M |
|
$-41.13M |
|
$-41.12M |
|
70.59M |
|
70.59M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$599.80M |
|
$0.01M |
|
$0.15M |
|
$599.95M |
|
$23.52M |
|
-- |
|
-- |
|
$23.52M |
|
$576.43M |
|
$576.43M |
|
$576.43M |
|
78.97M |
|
| Cash Flow Statement Financials | |
$-104.53M |
|
$-286.26M |
|
$494.30M |
|
$114.09M |
|
$217.60M |
|
$103.51M |
|
$14.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
25.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-104.53M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-6.41% |
-6.41% |
|
-6.16% |
|
-6.41% |
|
$7.30 |
|
$-1.48 |
|
$-1.48 |
|